Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,373.1
15.9 (0.47%)

 

  • STI Straits Times Index
    3,373.1
    15.9 (0.47%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,655.7
    0.3 (0.02%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,466.5
    95.2 (0.34%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,899.9
    13.0 (0.45%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,620.9
    204.1 (0.95%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,403.8
    -29.7 (-0.46%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,101.4
    8.1 (0.39%)
    Index delayed 20 minutes
  • XAO XAO
    6,812.5
    31.3 (0.46%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,090.1M
  • Value: 895.3M
  • Rise: 221
  • Fall: 157
  • Unch: 460

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sinwa0.047+0.016
DISA0.002-
Accrelist0.004+0.002
Singapore-eDev0.051+0.015
Jadason^0.045+0.005
Sino Grandness0.051+0.001
SingTel3.520-
Sen Yue0.039-
Genting Sing0.935+0.010
Tritech0.029-

World Indices

World Indices
Name Last Change
Nasdaq 8,204.1 +57.6
HSI 28,466.5 +95.2
HSCEI 10,809.9 +39.6
Jakarta 6,403.8 -29.7
Nikkei 225 21,620.9 +204.1
SSE Comp 2,899.9 +13.0
Shanghai A 3,037.4 +13.6
Shanghai B 287.4 +0.1
ShenZhen A 1,616.6 +14.1
ShenZhen B 967.4 +0.6
PSE Comp 0.0
KOSPI 2,101.4 +8.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

STEMLINE THERAPEUTICS INC STEMLINE THERAPEUTICS INC
Updated on 22 Jul 2019 (End of trading day)
Last (USD): 13.210 Change: -0.260 High: 13.590 Remarks: -
Change (%): -1.93 Low: 13.070
Open 13.500 Yesterday's Close 13.47
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 343,238 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -1.94631 Trailing EPS (USD) e -2.15211 NAV (USD) b 2.4927
PE a - Trailing PE f - Price / NAV b 5.2995
Dividend (USD) d - Cash In Hand (USD) g 0.5497 Issued & Paid-up Shares c 43,685,000
Dividend Yield (%) d - Price / Cash In Hand g 24.031 Treasury Shares h -
Beta - 75 Daysi -0.148 R-Squared - 75 Days(%)i 0.15 Market Cap (M) 577.079
Beta - 500 Daysi -0.194 R-Squared - 500 Days (%)i 0.34 Enterprise Value (M) 454.569
Piotroski F Score 2 Exchange Code STML Par Value ( $ ) n.a.
52 Weeks Volatility (%) 63.24 Free Float (%) 90.5
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 14 May 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference STEMLINE THERAPEUTICS INC NASDAQ 577.079 - - 5.2995 -
Industry Biotechnology NASDAQ 2,269.335 128.905 100.565 5.3938 0.788
Local Peer AMGEN INC NASDAQ 107,281.643 12.781 13.286 9.9042 3.099
Local Peer GILEAD SCIENCES INC NASDAQ 82,536.960 15.131 14.008 3.7601 3.541
Local Peer CELGENE CORP NASDAQ 63,099.612 15.596 13.298 7.7281 -
Local Peer BIOGEN INC NASDAQ 45,076.245 10.174 9.659 3.2593 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 44,585.544 21.268 20.691 9.4395 -
Local Peer ILLUMINA INC NASDAQ 43,847.160 53.084 51.524 11.0031 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,509.964 13.300 13.392 3.4421 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,428.670 353.465 65.871 2.8258 -
Local Peer INCYTE CORPORATION NASDAQ 17,521.811 160.027 69.271 8.4015 -
Local Peer EXACT SCIENCES CORP NASDAQ 14,986.581 - - 19.2893 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,612.194 - - 4.9759 -
Local Peer SEATTLE GENETICS INC NASDAQ 12,302.040 - - 9.6727 -
Other Local Peers SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RETROPHIN INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), OMEROS CORP (NASDAQ), MACROGENICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), PERSONALIS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), AVROBIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), SYNTHORX INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), MERUS B V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYNLOGIC INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), ATHERSYS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), MANNKIND CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), AFFIMED N V (NASDAQ), CHIMERIX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), IMV INC (NASDAQ), TOCAGEN INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), SESEN BIO INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NANTKWEST INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), VERASTEM INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SAVARA INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INFLARX N V (NASDAQ), OTONOMY INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CURIS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ORGENESIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VACCINEX INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CONTRAFECT CORP (NASDAQ), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HISTOGENICS CORP (NASDAQ), PRECIPIO INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), VICAL INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), OHR PHARMACEUTICAL INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), NEURALSTEM INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 101,018.277 45.273 41.466 14.6569 1.022
Global Peer AGILENT TECHNOLOGIES INC NYSE 21,831.956 69.089 19.545 4.2599 0.868
Global Peer SINO BIOPHARM HKEx 117,659.160 10.981 11.271 3.3944 0.782
Global Peer WUXI BIO HKEx 101,673.440 136.127 136.126 11.1536 -
Global Peer BEIGENE HKEx 59,869.452 - - 4.7407 -
Global Peer GENSCRIPT BIO HKEx 33,253.760 199.978 199.985 8.8734 -
Global Peer Lonza SGX 5,937.453 7.663 7.663 0.6889 4.766
Global Peer 3SBIO HKEx 32,796.835 21.680 21.680 3.3386 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,194.266 34.996 52.634 2.2220 -
Other Global Peers HAOHAI BIOTEC (HKEx), VIVA BIOTECH (HKEx), FRONTAGE (HKEx), ASCLETIS-B (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), MESOBLAST LTD (ASX), NEXT SCIENCE LTD (ASX), LEE'S PHARM (HKEx), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), KADMON HLDGS INC (NYSE), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), STANDARD DIVERSIFIED INC (NYSE American), ENZO BIOCHEM INC (NYSE), PALATIN TECHNOLOGIES INC (NYSE American), BBI LIFE SCI (HKEx), PFENEX INC (NYSE American), BIOTIME INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), UNI-BIO GROUP (HKEx), NEUREN PHARMACEUTICALS LTD (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PORT (SET), RESAPP HEALTH LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), IBIO INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CEL-SCI CORP (NYSE American), REGENT PACIFIC (HKEx), CT ENTERPRISE (HKEx), IMMUTEP LTD (ASX), ORTHOCELL LIMITED (ASX), PHYLOGICA LIMITED (ASX), IMUGENE LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ZELDA THERAPEUTICS LTD (ASX), BIOTRON (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), RHINOMED LIMITED (ASX), EXTRAWELL PHAR (HKEx), MEMPHASYS LTD (ASX), BIOSINO BIO-TEC (HKEx), ONCOSIL MEDICAL LIMITED (ASX), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), ADALTA LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), PATRYS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), KAZIA THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), NANOVIRICIDES INC (NYSE American), IMMURON LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), Suntar Eco-City^ (SGX), ANATARA LIFESCIENCES LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOXYNE LIMITED (ASX), BENITEC BIOPHARMA LTD (ASX), QT Vascular (SGX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), MEDIBIO LIMITED (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.210
+1.62 %
10 Days --1.190
-8.26 %
20 Days --1.610
-10.86 %
Medium Term Return 3 Months --0.800
-5.71 %
6 Months -+2.600
+24.51 %
1 Year --2.690
-16.92 %
Long Term Return 2 Years -+3.360
+34.11 %
3 Years -+5.940
+81.71 %
5 Years -+0.410
+3.20 %
Annualised Return Annualised --
+0.63 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 7.820 - 17.850 Change From 1 Year Low +5.390 % Change From 1 Year Low (%) +68.93
Change From 1 Year High -4.640 % Change From 1 Year High (%) -25.99
2 Years Range 7.300 - 20.550 Change From 2 Years Low +5.910 % Change From 2 Years Low (%) +80.96
Change From 2 Years High -7.340 % Change From 2 Years High (%) -35.72
5 Years Range 3.880 - 20.550 Change From 5 Years Low +9.330 % Change From 5 Years Low (%) +240.46
Change From 5 Years High -7.340 % Change From 5 Years High (%) -35.72
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Jul 2019 13.500 13.590 13.070 13.210 343,238 -
19 Jul 2019 13.810 13.810 13.460 13.470 269,856 -
18 Jul 2019 13.300 13.840 13.300 13.820 263,661 -
17 Jul 2019 13.020 13.340 12.750 13.270 300,633 -
16 Jul 2019 12.620 13.110 12.620 13.000 523,823 -
15 Jul 2019 13.260 13.380 12.540 12.610 531,565 -
12 Jul 2019 14.010 14.180 13.190 13.210 577,515 -
11 Jul 2019 14.710 14.810 13.990 14.010 296,036 -
10 Jul 2019 14.550 14.850 14.350 14.640 349,176 -
09 Jul 2019 14.100 14.600 14.095 14.400 293,891 -
08 Jul 2019 14.360 14.540 14.000 14.320 284,469 -
05 Jul 2019 14.570 14.685 14.365 14.480 242,793 -
03 Jul 2019 14.240 14.650 14.200 14.620 234,437 -
02 Jul 2019 14.940 15.020 14.090 14.190 438,393 -
01 Jul 2019 15.580 15.700 14.760 14.880 374,065 -
28 Jun 2019 15.010 15.400 14.950 15.320 1,256,921 -
27 Jun 2019 14.520 15.350 14.400 15.080 518,890 -
26 Jun 2019 14.940 15.085 14.380 14.500 522,333 -
25 Jun 2019 14.970 15.290 14.620 14.820 433,082 -
24 Jun 2019 15.730 15.870 14.720 14.740 569,996 -
21 Jun 2019 15.700 16.130 15.120 15.920 1,042,203 -
20 Jun 2019 15.900 16.000 15.290 15.800 458,487 -
Summary
Current 2 Weeks
(09 Jul 2019 to 22 Jul 2019)
14.100 14.850 12.540 13.210 3,749,394 -
Previous 2 Weeks
(24 Jun 2019 to 08 Jul 2019)
15.730 15.870 12.540 14.320 4,875,379 -
4 Weeks from
(24 May 2019 to 21 Jun 2019)
14.840 15.010 12.540 15.920 7,766,827 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.